NCT05642780 2025-10-14SKB264 in Combination With Pembrolizumab in Subjects With Selected Solid TumorsKlus Pharma Inc.Phase 2 Active not recruiting240 enrolled
NCT02608385 2025-06-08Study of PD1 Blockade by Pembrolizumab With Stereotactic Body Radiotherapy in Advanced Solid TumorsUniversity of ChicagoPhase 1 Active not recruiting117 enrolled